Evaluation of safety and the effectiveness of Caffeine Plus Irox anti-hair loss serum and shampoo

Phase 2

Recruiting

• Conditions: hair loss.; Nonscarring hair loss, unspecified; L65.9

• Registration Number: IRCT20190210042676N13
• Lead Sponsor: Iran Avandfar Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

Male aged 18-55 years
Good general health
Voluntary participation and sign the written informed consent
Hair Loss Status II, III, IV based on Norwood Scale

Exclusion Criteria

Chronic active scalp disease other than hair loss
Using any prescribed drug or OTC for hair loss within the past 3 months
People with allergies to serum and shampoo ingredients
Any severe weight loss or strict diet therapy during the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hair lost Changes, based on Global photographic review. Timepoint: Before intervention, 6 and 12 weeks after the start of use. Method of measurement: One independent dermatologist will perform clinical assessments in a blinded fashion by scoring every photograph according to the Global photographic review scale .

Secondary Outcome Measures

Name	Time	Method
Hair count changes. Timepoint: Before intervention, 6 and 12 weeks after the start of use. Method of measurement: Trichoscopy By Fotofinder.;Changes in percentage of anagen to telogen. Timepoint: Before intervention, 6 and 12 weeks the start of use. Method of measurement: Trichoscopy By Fotofinder.